Ozempic and Wegovy Linked to Surprising Drop in Violent Behavior

New Delhi, India Jun 17, 2026 ALN: Popular GLP-1 medications such as Ozempic and Wegovy are best known for helping people lose weight and manage diabetes. New research from Rutgers University suggests these drugs may also be linked to changes in behaviors associated with violence. This finding is particularly intriguing given the growing prevalence of these medications in the treatment of obesity and type 2 diabetes, conditions that affect millions of people worldwide.

The study, published in Criminology, investigated whether GLP-1 receptor agonists influence violent criminal behavior in adults. Researchers focused on whether the medications might alter the effects of two factors that are strongly connected to violence: impulsivity and alcohol consumption. Understanding the intersection of mental , medication, and behavior is crucial, especially as public initiatives increasingly emphasize holistic approaches to treatment.

GLP-1 Drugs and Violent Behavior

To explore the question, researchers analyzed data from a 2025 survey involving 7,521 adults across the United States. Their main analysis concentrated on 821 people who had used a GLP-1 medication at some point. This demographic detail is significant as it reflects a diverse population that can provide insights into varying behavioral responses to the medication.

The team compared current users with former users and examined how medication use affected the relationship between violent behavior, impulsivity, and alcohol use. Violent behavior was assessed using a validated self-report measure that included actions such as fighting, assault, and robbery. This methodology ensures that the findings are grounded in empirical evidence, allowing for a more nuanced understanding of the potential behavioral impacts of these medications.

"The strongest finding in the study was that the well-established link between impulsivity and violent behavior was substantially weaker among current GLP-1 users compared to former users," said Daniel Semenza, the lead author of the study as well as the director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public and an associate professor with the Rutgers School of Public. This statement underscores the potential implications of the findings for public safety and mental treatment.

"As GLP-1 drugs become increasingly widespread, it is important to understand all of their potential behavioral effects, including those relevant to public safety," Semenza said. This perspective highlights the necessity of ongoing research into the broader impacts of medications that are rapidly becoming integral to the treatment landscape for obesity and diabetes.

Impulsivity and Alcohol Effects Were Weaker

Across the full sample, higher levels of impulsivity and greater alcohol use were both strongly linked to violent behavior. However, those connections were significantly less pronounced among people who were currently taking GLP-1 medications. This observation raises critical questions about the mechanisms through which these medications may influence behavior, particularly in populations at risk for violence.

According to the researchers, the relationship between impulsivity and violent behavior was about 62% weaker among current users than among former users. The connection between alcohol use and violent behavior was about 52% weaker among current users, although those results were not as consistent across additional sensitivity analyses. These statistical findings suggest a significant alteration in behavioral patterns among users of GLP-1 medications, which could have far-reaching implications for both clinical practice and public policy.

"Our findings are consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself," said Christopher Thomas, an assistant professor at Rutgers University-Camden and the coauthor of the study. This analogy to cognitive behavioral therapy suggests that GLP-1 drugs may help individuals manage their responses to impulses in a manner that reduces the likelihood of violent behavior, thereby enhancing overall community safety.

More Research Is Needed

The researchers cautioned that the study cannot prove that GLP-1 medications directly reduce violent behavior. Because the research was observational and cross-sectional, it can only identify associations rather than cause-and-effect relationships. This limitation is important to consider, as establishing causation is critical in the field of behavioral and pharmacology.

The team said future longitudinal and experimental studies will be needed to determine whether GLP-1 medications truly lower violence risk and to better understand the biological and behavioral mechanisms that may be involved. Such research could pave the way for new interventions that leverage the behavioral benefits of GLP-1 medications, potentially transforming approaches to violence prevention and treatment for impulsivity-related disorders.

In the broader context, the implications of this research could extend into various fields, including criminal justice, public , and mental treatment. As the prevalence of obesity and related metabolic disorders continues to rise, understanding the multifaceted effects of treatments like GLP-1 medications becomes increasingly vital. If these medications can indeed play a role in reducing violent behavior, they may not only improve individual outcomes but also contribute to safer communities.

Moreover, the findings may encourage care providers to consider the psychological effects of medications when prescribing treatments for obesity and diabetes. This could lead to more comprehensive care strategies that address both physical and behavioral , ultimately improving patient outcomes across the board. As society grapples with issues of violence and public safety, the intersection of pharmacological treatment and behavioral will likely remain a critical area of inquiry for researchers and practitioners alike.